SurModics Elects Robert C. Buhrmaster Chairman of the Board
Kendrick B. Melrose to Retire
EDEN PRAIRIE, Minn.--(BUSINESS WIRE)--
SurModics, Inc. (Nasdaq: SRDX), a leading provider of drug delivery and
surface modification technologies to the healthcare industry, announced
that its board of directors has elected Robert C. Buhrmaster chairman of
the board, effective at today's Annual Meeting of Shareholders.
Buhrmaster succeeds Kendrick B. Melrose, 68, who is retiring from the
Company’s board of directors. Melrose has been chairman of the board
since August 2006, and has been a director since 1988.
Buhrmaster, 61, has been a director of SurModics since January 2008. He
previously served as the President and Chief Executive Officer of
Jostens, Inc., from 1994 to 2004 and as Chairman from 1998 to 2004.
Prior to joining Jostens, Mr. Buhrmaster spent 18 years at Corning,
Inc., serving in various roles, including senior vice president and
general manager of several businesses, corporate controller and director
of strategic planning.
“Serving as a board member has been a very rewarding experience for me.
I will greatly miss the interactions with such a highly accomplished
group of professionals and community leaders," said Melrose. "I am
honored to pass the chairmanship to Bob Buhrmaster, who brings
tremendous depth of experience and keen business insights to his new
role. His strategic sense and practical judgment have been important
assets for the board and the management team. I have great confidence in
Bob, the entire board, and the management team's ability to continue
leading SurModics toward its vast potential in developing and
commercializing life-enhancing technologies and products."
“I am delighted to have the opportunity to lead the SurModics board,"
said Buhrmaster. "It will be a privilege to succeed Ken Melrose, an
outstanding chairman, in this role. I look forward to working even more
closely with Bruce Barclay and his talented management team.”
“I want to thank Ken for his 20 years of tireless efforts on behalf of
SurModics,” said Bruce Barclay, president and CEO. “His contributions to
the success of this company are immeasurable, and he has been critical
in helping drive our tremendous diversification and growth. We are
extremely fortunate to have Bob Buhrmaster, an experienced advisor and
skillful business leader, to succeed him. I look forward to teaming with
Bob as SurModics continues to pursue its vision of extending and
improving the lives of patients through technology innovation."
About SurModics, Inc.
SurModics’ vision is to extend and improve the lives of patients through
technology innovation. The Company partners with the world’s foremost
medical device, pharmaceutical and life science companies to develop and
commercialize innovative products that result in improved diagnosis and
treatment for patients. Core offerings include: drug delivery
technologies (coatings, microparticles, nanoparticles, and implants);
surface modification coating technologies that impart lubricity,
prohealing, and biocompatibility capabilities; and components for in
vitro diagnostic test kits and specialized surfaces for cell culture and
microarrays. SurModics is headquartered in Eden Prairie, Minnesota and
its Brookwood Pharmaceuticals subsidiary is located in Birmingham,
Alabama. For more information about the Company, visit www.surmodics.com.
The content of SurModics’ website is not part of this release or part of
any filings the Company makes with the SEC.
Source: SurModics, Inc.
Phil Ankeny, Senior Vice President and Chief